ALBO News and Press, Albireo Pharma Inc. From 09/02/21

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of t...

The expectation is that Mirum trades two-fold higher or more on regulatory approval of maralixibat for Alagille syndrome, and better than Albireo’s lackluster share price performance post-regulatory successes in PFIC. Regulatory approval for MIRM represents a significant clinic...

We are going to circle back on small-cap biotech concern Albireo Pharma in today's research piece. The company has garnered FDA approval since we last took a look at it in Spring. However, given the poor sentiment on the biotech sector, the shares haven't budged yet. We update our...

Albireo Pharma, Inc. (ALBO) Q2 2021 Earnings Conference Call August 05, 2021 10:00 AM ET Company Participants Paul Arndt - Managing Director of LifeSci Advisors Ron Cooper - President and Chief Executive Officer Simon Harford - Chief Financial Officer Pamela Stephenson - Chief Commercial Offi...

Image source: The Motley Fool. Albireo Pharma, inc (NASDAQ: ALBO) Q2 2021 Earnings Call Aug 6, 2021 , 2:30 p.m. ET Operator Continue reading For further details see: Albireo Pharma, inc (ALBO) Q2 2021 Earnings Call Transcript

The following slide deck was published by Albireo Pharma, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Albireo Pharma, Inc. 2021 Q2 - Results - Earnings Call Presentation

– Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC – – Commercialization underway with Bylvay, first prescriptions received in the U.S. – – German price listi...

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021...

BOSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on August 5, 2021, to provide a bu...

– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by...